Replies to post #125059 on Biotech Values

[biotech jim]

Does Dr. Topol understand "outcomes" trials, where the required number of cardiac events are needed for statsig? Many of the trials he was referring were such outcomes trials, that the FDA required for approval for such indications (like reducing the risk of an MI).